ProCE Banner Activity

CME

Contemporary Management of Hemophilia A: Expert Guidance to Improve Patient Outcomes—Updated

Multimedia
With updates from ASH 2020, current management of hemophilia A is discussed by a panel of experts in this on-demand Webcast from a live Webinar.

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: February 25, 2021

Expiration: February 24, 2022

No longer available for credit.

Share

Faculty

Miguel A. Escobar

Miguel A. Escobar, MD

Professor of Medicine and Pediatrics
Division of Hematology
McGovern Medical School
Director
Gulf States Hemophilia and Thrombophilia Center
Houston, Texas

Michael Callaghan

Michael Callaghan, MD

Associate Professor
Department of Hematology
Wayne State University
Hematologist
Division of Hematology/Oncology
Childrens Hospital of Michigan
Detroit, Michigan

Rebecca Kruse-Jarres

Rebecca Kruse-Jarres, MD, MPH

Professor
Department of Medicine
University of Washington
Executive/Medical Director
Washington Institute for Coagulation
Seattle, Washington

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Genentech, a member of the Roche Group

Sanofi Genzyme Corp

Takeda Pharmaceutical Co Ltd

Target Audience

This program is intended for hematologists and other clinicians involved in the management of patients with hemophilia A.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Implement individualized hemophilia A management strategies that optimize adherence, outcomes, and utilization of resources
  • Analyze recent data on the efficacy, safety, and tolerability of emerging nonfactor replacement strategies for the management of hemophilia A with and without inhibitors
  • Discuss progress in the management of hemophilia A with factor-based interventions, including use of extended half-life agents
  • Mitigate and manage complications and comorbidities in patients receiving prophylaxis for hemophilia A
  • Develop approaches for individualizing therapy based on patient-specific and disease-specific characteristics
  • Evaluate available data for novel agents and treatment strategies and determine patients with hemophilia A who may be eligible for a clinical trial

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director Disclosure

Program Director

Miguel A. Escobar, MD

Professor of Medicine and Pediatrics
Division of Hematology
McGovern Medical School
Director
Gulf States Hemophilia and Thrombophilia Center
Houston, Texas

Miguel A. Escobar, MD, has disclosed that he has received consulting fees from CSL Behring, Biomarin, Genentech/Roche, Kedrion, NHF, Novo Nordisk, Pfizer, Sanofi, and Takeda and funds for research support paid to his institution from CSL Behring, Genentech, Novo Nordisk, Sanofi, Takeda, and UniQure.

Faculty Disclosure

Primary Author

Michael Callaghan, MD

Associate Professor
Department of Hematology
Wayne State University
Hematologist
Division of Hematology/Oncology
Childrens Hospital of Michigan
Detroit, Michigan

Michael Callaghan, MD, has disclosed that he has received consulting fees from Bayer, BioMarin, Catalyst, Genentech/Roche, Global Blood Therapeutics, Hema Biologics, Kedrion, Pfizer, Sanofi, Spark, Takeda, and UniQure and has ownership interest in Alnylam.

Rebecca Kruse-Jarres, MD, MPH

Professor
Department of Medicine
University of Washington
Executive/Medical Director
Washington Institute for Coagulation
Seattle, Washington

Rebecca Kruse-Jarres, MD, MPH, has disclosed that she has received consulting fees from BioMarin, CRISPR, CSL Behring, and Genentech/Roche; funds for research support from CSL Behring and Genentech/Roche; and fees for non-CME/CE services from Genentech/Roche; and that her spouse/partner has received consulting fees, funds for research support, and fees for non-CME/CE services from Genentech/Roche and fees for non-CME/CE services from Sanofi.

Staff Disclosure

Staff

Marie N. Becker, PhD

Scientific Director

Marie N. Becker, PhD, has no relevant conflicts of interest to report.

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, had no relevant conflicts of interest to report.

Elizabeth O’Connell, PhD

Elizabeth O’Connell, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 25, 2021, through February 24, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge and competence of learners in using novel curative and noncurative therapeutic options for patients with hemophilia A.